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CORRESPONDENCE 
 
In Reply – Dietz and colleagues raise several issues in relation to our 
article on the assignment of a second locus for MFS: the legitimacy of the MFS 
diagnosis the reliability of the clinical investigations and hence the validity of 
our linkage analyses, and so question our conclusion of genetic heterogeneity in 
MFS. 
 
The diagnosis of MFS was recognized in our family repeatedly and 
independently by several clinicians before 1986, when the « Berlin nosology2 » 
was proposed. After 1986, this diagnosis remained unchanged, notably in 
subject III-38, when using these recognized criteria. This patient died of an 
acute aortic dissection and his necropsy showed skeletal abnormalities (height 
186 cm, arachnodactyly, pectus excavatum), a past history of surgery for 
inguinal hernia, and dilation of the ascending aorta4. Contrary to the 
authors’claim, there is no reference in the « Berlin nosology » to the lack of 
diagnostic significance of a specific physical feature that is not observed in the 
rest of the family. Eleven other family members (III-4, III-32, III-36, III-37, III-
38, III-40, III-42, IV-6, IV-10, IV-49, IV-51) are also considered affected using 
the same criteria. Furthermore, it cannot be ignored that IV-6 died suddenly at 
nine years of age after complaining of chest pains, III-32, III-38 and III-42 died 
of ascertained aortic dissection (a major unquestionable diagnostic criteria for 
MFS) and III-49 was operated upon for aortic dissection (histologic studies, 
compatible with the diagnosis and performed in independent institutions from 
ours, are available for subjects III-32, III-38 and III-49). In addition II-3, II-7 
and III-32 are obligate carriers. Because of the absence of ocular involvement, 
we were compelled to re-name the syndrome «Marfan-like» or even « a new 
connective-tissue disorder ». However, prominent figures in the field10 (and the 
reviewers of our paper1) did not endorse this volte-face and considered MFS as 
the diagnosis, based on the original clinical features of the family published in 
1993 (ref.4). 
 
In contrast, Dietz et al. disprove the diagnosis. This is their right. However, 
we cannot accept their biased reinterpretation of our data which is performed 
with a mind set on demonstrating the existence of two independent genetic traits 
in this family and in which each clinical feature is weighed one by one 
regardless of the overall clinical presentation of a given individual. Despite their 
claim that the normalization methods they used are « the same3» as comparable 
to those we reported, this is not the case. In effect, with their methods, stature is 
abnormal in only 11 subjects (versus 18 as compared to the French normal 
values (see ref. 4) and the upper segment-to-lower segment ratio is aberrant in 
11 patients, none of which have short limbed dwarfism. 
 
Similarly, the criteria they used to standardize our aortic diameter 
measurements were obtained with a different technique applied to a different 
level of the aorta6. In effect, we used M-mode guided by two dimensional (2-D) 
echocardiography (and not 2-D echocardiography alone) and measured the 
aortic diameter always at the same level, namely when 2 aortic cusps were 
visualized12 (and not the widest diameter of the sinuses of Valsalva). As 
reported by Roman et al6, the M-mode diameter is smaller than the diameter 
measured at the same level by 2-D echocardiography (30.9  4.2 vs 29.8  3.9; 
p<0.05) and of course smaller than the widest diameter of the aorta at the level 
termed «sinuses of Valsalva» by these authors (31.7  3.9 vs 29.8  3.9; 
p<0.01)6. As a particularly striking example, individual III-52, who has an aortic 
M-Mode diameter of 39 mm (> mean +2 SD with the proper normalization 
reported in 1993), has an aortic diameter of 48 mm when measured with 2-D 
echocardiography according to the Roman et al.6 (also > mean + 2 SD). 
Consequently, it is not surprising that Dietz et al, find aortic dilation in only 4 
individuals. This is in sharp contrast to our data, derived from the appropriate 
normalizing procedure12, which revealed aortic dilation in 13 family members. 
Finally, contrary to what Dietz and colleagues claim, this normalizing 
procedure12 does take into account age as well as body surface area and is 
widely accepted. 
 
Disregarding the manipulation of our published data, the dispute is clearly 
based upon the examination of the family at large, which lacks one of the major 
criteria for the diagnosis of MFS (such as eye involvement). But a family of this 
size is exceptional. We believe that the issue is not whether this is a genuine 
MFS but is: which diagnosis could unambiguously be made in similar patients 
in the absence of sufficient family data for linkage analysis or discriminating 
biological markers? 
 
Our family has been under investigation for many years. Since several 
clinicians had independently evaluated family members (phenotypic status as 
given in ref. 5), all members were re-assessed using more stringent criteria4. 
This led to a change in phenotypic status of some individuals as Dietz et al. 
correctly note. 
 
Correct discrimination between affected and unaffected individuals is critical for 
linkage analysis. However, no absolute and definitive rule could be used in the 
family: the international criteria2 were clearly inadequate since at least one 
member (III-49), operated upon because aortic dissection, would not have been 
recognized by these criteria. Consequently, we developed a pragmatic « case by 
case » approach4, which in effect refers to the actual clinical follow-up of these 
patients. With this classification, we confirmed the exclusion data previously 
reported with the collagen genes5, excluded linkage to the fibrillin genes4, 
constructed an exclusion map, and established conclusive linkage with 3p 
markers1. In this family, an autosomal dominant disease gene segregates which 
can be mapped by exclusion mapping13. The most likely location is where the 
highest lod score is obtained. Our lod score is high and remains significant even 
if we take into account the large number of tests that were performed. Indeed, 
the 144 markers we studied correspond approximately to 70 independent tests. 
Since the probability that one of them reaches the 4.89 value is only 1 per 1,000 
(ref.14), linkage is established in this family. Furthermore, all the two point, lod 
scores were computed with complete penetrance. Changing the penetrance at 
that stage of the analysis would have substantially raised our highest lod score 
value but was not done. However, the haplotype analysis that was done in the 
family (after linkage was established) clearly showed that the penetrance was 
not complete with the clinical criteria we had used to classify family members. 
Therefore, it was solely to refine the map position of MFS2 with the LINKMAP 
program that we changed the value of this parameter since the misspecification 
of penetrance has a strong effect on  (ref.15). 
 
Finally, the last issue raised by Dietz et al. is that of genetic heterogeneity. 
Our belief in genetic heterogeneity in MFS stems not only from the linkage data 
in our family, but also from published data showing that it has been impossible 
to identify mutations in the fibrillin gene in a number of patients and that in 
some individuals with « definite Marfan syndrome » no anomaly was observed 
in fibrillin metabolism. Although it is likely that normal fibrillin metabolism 
does not exclude the presence of an abnormal fibrillin associated with 
perturbation of microfibrillar structure and function, microfibrils contain not 
only fibrillin but also other components. Therefore, it is also possible that these 
MFS patients have abnormal microfibrillar structure or function due to 
anomalies carried by another component or by proteins associated with 
microfibrils. This interpretation has never been seriously considered and no 
effort has been undertaken to investigate fully the question of genetic 
heterogeneity despite knowledge, as early as 1991 (refs 16,17), that in the 
French family the mutation locus was not MFS1 (fibrillin). Consequently, it is 
not surprising that in a family in which fibrillin haplotypes did not segregate in 
all affected members, heterogeneity was not evoked. The absence of 
cosegregation was explained by the simultaneous existence of two different 
connective-tissue disorders (MFS and another still unknown)18, a very unlikely 
situation except if one is willing to consider that connective-tissue disorders are 
frequent. More alarmingly, under the cover of homogeneity, haplotype analyses 
with fibrillin polymorphic markers were used for diagnosis in an at-risk 
individual, in a small family in which the presence of a fibrillin defect had not 
been conclusively demonstrated18. 
 
Indeed, genetic heterogeneity for MFS is a major issue to which our results 
make a significant contribution and which now requires a large objective and 
open-minded collaborative effort, in the interest of patients and their families. 
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